People
Social distancing has become the new norm in the attempt to prevent the spread of COVID-19, and that norm could become a mainstay of life for the next couple years, a new study suggests.
Cerevance secured $45 million in a Series B financing round to support the development of its therapeutics for central nervous system diseases, including Alzheimer’s and Parkinson’s disease.
Origin, a 3D printing specialist for medical devices, just completed clinical trials and validation of its 3D-printed nasopharyngeal swabs for use in COVID-19 test kits. It is scaling up production and accepting orders to manufacture millions of the swabs.
The investigators assayed the levels and analyzed the expression patterns of more than 3,000 proteins in brain and cerebrospinal fluid samples collected at centers across the U.S.
Although the COVID-19 death toll has not yet reached the numbers of H3N2, it still continues to climb.
In its daily blog about the precautions the company is taking to ensure continued service to the world, Amazon said it will build its own testing facilities for employees.
On Thursday, the American Medical Association doubled down on its stance against using off-label medicines like hydroxychloroquine and chloroquine to treat COVID-19 patients.
As COVID-19 has swept across the world, companies have had to make significant adjustments to the way business is conducted in a global economy. It has impacted all types of operations, including clinical trials.
Biopharma companies strengthen their leadership teams and boards with this week’s Movers & Shakers.
If you’re having trouble keeping up with multiple industry programs aimed at COVID-19, you’re not alone. But, there is a new solution that can help you see the proverbial forest from the trees – Signals Analytics COVID-19 Playbook.
PRESS RELEASES